Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, bringing the total number of formulary platforms covering neffy to 30 Feb. 20, 2025 -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, annou

In January 2025, the global pharmaceutical industry's investment and licensing activities demonstrated a strong interest in novel treatment methods and technologies. From rare disease treatments to cardiovascular disease management, and groundbreaking advancements in oncology, this month’s collaborations encompassed various indications and innovative technologies. AB2 Bio's collaboration with Nippon Shinyaku focused on treating rare pediatric diseases with Tadekinig alfa, a novel recombinant hum

In January 2025, the pharmaceutical collaborations and transactions showcased a diversified trend of development, ranging from multinational pharmaceutical corporations to startup biotech enterprises. Each party is actively exploring new partnership models and technological platforms. Initially, the collaboration between Simcere Zaiming and AbbVie marks their dedication to combating the complex disease of multiple myeloma. The SIM0500 project, based on T-cell engaging bispecific antibody technol

With the thriving development of the biopharmaceutical industry, January 2025 witnessed several significant financing events exceeding $100 million, infusing fresh resources into pioneering companies dedicated to addressing unmet medical needs. For many startups focused on developing next-generation therapies and technologies, this period of fundraising activities represents a crucial milestone in achieving scientific breakthroughs and advancing commercialization of their products. Whether conce

Study results of novel drug-eluting technology highlight potential durability of TAR-200 in patient population with high unmet need CHICAGO, April 30, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the open-label Phase 2 SunRISe-1 study evaluating the efficacy and safety of TAR-200 monotherapy (a novel investigational intravesical drug delivery system) and cetrelimab monotherapy (an investigational anti-PD-1 monoclonal antibody administere

As the global pharmaceutical market continues to expand and China's biopharmaceutical industry rapidly advances, in January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally. From Innovent Biologics' collaboration with Roche on IBI3009 to Lepu Biopharma's licensing agreement with ArriVent for MRG007, these actions highlight the significant role Chinese biopharmaceuticals play in the globalization process. 1.Innoven

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025 FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5 Feb. 18, 2025 -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the tr

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 Feb. 18, 2025 -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers. SEP-

Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presented in December 2024 at the American Society of Hematology showing clinical benefits of sotagliflozin compared to empagliflozin Feb. 18, 2025 -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to reduce the risks of life-threatening cardio

In January 2025, a series of collaborative agreements were successively reached in the field of antibody-based pharmaceuticals in China: WuXi Biologics partnered with Candid Therapeutics to advance the development of a BCMA, CD20, and CD19 tri-specific antibody therapy through its WuXiBody™ platform. This groundbreaking partnership indicates a new direction for future oncological immunotherapy. Concurrently, Keymed Biomedical's CD38 monoclonal antibody, CM313, was successfully licensed to Timber